Advertisement

Loading...

Lepu Biopharma Co., Ltd.

2157.HKHKSE
Healthcare
Biotechnology
HK$6.00
HK$0.66(12.36%)
Hong Kong Market is Open • 10:07

Lepu Biopharma Co., Ltd. (2157.HK) Stock Competitors & Peer Comparison

See (2157.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2157.HKHK$6.12+13.12%9.6B31.41HK$0.17N/A
6160.HKHK$184.70+7.95%257.8B115.17HK$1.49N/A
1801.HKHK$90.45+5.05%146.1B160.19HK$0.53N/A
2269.HKHK$34.96+11.48%136.5B25.21HK$1.31N/A
9926.HKHK$138.80+4.28%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.35+8.55%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.14+3.54%53.4B20.77HK$1.09+1.10%
9995.HKHK$108.90+10.17%52.7B65.62HK$1.46N/A
3759.HKHK$20.70+13.30%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.40+8.26%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2157.HK vs 6160.HK Comparison April 2026

2157.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2157.HK stands at 9.6B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 2157.HK is priced at HK$6.12, while 6160.HK trades at HK$184.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2157.HK currently has a P/E ratio of 31.41, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 2157.HK's ROE is +0.24%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 2157.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2157.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions